18F-Fluciclovine PET代谢显像揭示前列腺癌肿瘤异质性与雄激素剥夺治疗耐药相关
研究采用人前列腺癌原位移植瘤模型(雄激素敏感CWR22Res与去势抵抗22Rv1),在急性与慢性雄激素剥夺治疗(ADT)后行纵向18F-Fluciclovine PET显像。结果显示显像摄取与存活癌细胞相关,SUVpeak与变异系数(CoV)反映肿瘤异质性,氨基酸转运体表达随ADT模式不同而变化,提示该显像可能作为去势抵抗的临床生物标志物。
要点
- 18F-Fluciclovine摄取与雄激素充足及去势环境下存活癌细胞相关。
- ADT后SUVpeak与CoV可反映肿瘤异质性,可能解释去势抵抗。
- 慢性ADT后LAT1相关基因SLC7A5/SLC3A2在22Rv1中高表达。
核心结论
- 18F-Fluciclovine PET显像可揭示前列腺癌肿瘤异质性,可能解释去势抵抗并作为临床生物标志物。
研究设计与样本
- 将雄激素敏感CWR22Res与去势抵抗22Rv1人前列腺癌细胞植入CD-1 Nu小鼠前列腺前叶建立原位移植瘤模型。
主要发现
- 免疫组化与纵向18F-Fluciclovine显像均显示肿瘤异质性,尤其在ADT后。
- 体内18F-Fluciclovine摄取与雄激素充足及去势环境中存活癌细胞相关。
- ADT后SUVpeak与变异系数(CoV)与免疫组化揭示的肿瘤异质性一致。
- 慢性ADT后22Rv1去势抵抗移植瘤中SLC7A5与SLC3A2表达相对较高。
- 急性ADT后CWR22Res肿瘤中SLC1A5优先表达。
关键数值与推荐
- 18F-Fluciclovine放射化学纯度>99%,在FASTlab合成器上生产。
临床怎么用
- 18F-Fluciclovine PET显像的SUVpeak与CoV有望用于早期识别前列腺癌ADT耐药与肿瘤异质性。
局限性
- 研究基于人前列腺癌原位移植瘤小鼠模型,非临床患者数据。
- 其他氨基酸转运体如SLC43A2(LAT4)在Fluciclovine摄取中的作用尚待研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer is highly prevalent worldwide. Androgen deprivation therapy (ADT) remains the treatment of choice for incurable prostate cancer, but majority of patients develop disease recurrence following ADT. There is therefore an urgent need for early detection of treatment resistance. METHODS: Isogenic androgen-responsive (CWR22Res) and castration-resistant (22Rv1) human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts. Castrated mice bearing CWR22Res and 22Rv1 orthografts mimic clinical prostate cancer following acute and chronic ADT, respectively. 18F-Fluciclovine (1-amino-3-fluorocyclobutane-1-carboxylic acid) with a radiochemical purity of > 99% was produced on a FASTlab synthesiser. Ki67 staining in endpoint orthografts was studied. Western blot, quantitative RT-PCR and next-generation sequencing transcriptomic analyses were performed to assess the expression levels of amino acid transporters (including LAT1 and ASCT2, which have been implicated for Fluciclovine uptake). Longitudinal metabolic imaging with 18F-Fluciclovine-based positron emission tomography (PET) was performed to study tumour response following acute and chronic ADT. RESULTS: Both immunohistochemistry analysis of endpoint prostate tumours and longitudinal 18F-Fluciclovine imaging revealed tumour heterogeneity, particularly following ADT, with in vivo 18F-Fluciclovine uptake correlating to viable cancer cells in both androgen-proficient and castrated environment. Highlighting tumour subpopulation following ADT, both SUVpeak and coefficient of variation (CoV) values of 18F-Fluciclovine uptake are consistent with tumour heterogeneity revealed by immunohistochemistry. We studied the expression of amino acid transporters (AATs) for 18F-Fluciclovine, namely LAT1 (SLC7A5 and SLC3A2) and ASCT2 (SLC1A5). SLC7A5 and SLC3A2 were expressed at relatively high levels in 22Rv1 castration-resistant orthografts following chronic ADT (modelling clinical castration-resistant disease), while SLC1A5 was preferentially expression in CWR22Res tumours following acute ADT. Additional AATs such as SLC43A2 (LAT4) were shown to be upregulated following chronic ADT by transcriptomic analysis; their role in Fluciclovine uptake warrants investigation. CONCLUSION: We studied in vivo 18F-Fluciclovine uptake in human prostate cancer orthograft models following acute and chronic ADT. 18F-Fluciclovine uptakes highlight tumour heterogeneity that may explain castration resistance and can be exploited as a clinical biomarker.
引用
- Malviya G, Patel R, Salji M, et al. 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. EJNMMI Res. 2020. PMID: 33237350. doi:10.1186/s13550-020-00728-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。